Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 21.17% is 38% below its 4-year average of 34.25%, near the low end of its 4-year range (12.54%–71.72%).
As of the fiscal period ended Wednesday, December 31, 2025. 25.60% above its 12-month average of 16.86%.
Reported quarterly return on assets; no daily interpolation. Q4 FY2025 (2025-12-31): 10.05%.
RETURN ON ASSETS (ROA)
21.17%
RETURN ON ASSETS (ROA) AVG TTM
16.86%
RETURN ON ASSETS (ROA) AVG 3Y
29.92%
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+25.60%
CURRENT VS 3Y AVG
-29.24%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+165.61%
vs the sector median at left
Anbio Biotechnology Class A Ordinary Shares
Market Cap
$215.07M
Return on Assets (ROA)
21.17%
TTM Avg
16.86%
3Y Avg
29.92%
5Y Avg
N/A
Market Cap
$214.46M
Return on Assets (ROA)
-34.38%
TTM Avg
-28.15%
3Y Avg
-48.34%
5Y Avg
-48.34%
Market Cap
$214.24M
Return on Assets (ROA)
15.00%
TTM Avg
14.43%
3Y Avg
-2.68%
5Y Avg
-18.26%
Market Cap
$216.91M
Return on Assets (ROA)
-31.94%
TTM Avg
-71.44%
3Y Avg
-59.77%
5Y Avg
-50.19%
Market Cap
$218.30M
Return on Assets (ROA)
-28.91%
TTM Avg
-2.34%
3Y Avg
-20.04%
5Y Avg
-20.00%
Market Cap
$210.98M
Return on Assets (ROA)
-79.86%
TTM Avg
-75.29%
3Y Avg
-50.35%
5Y Avg
-41.02%
Market Cap
$210.41M
Return on Assets (ROA)
-55.47%
TTM Avg
-12.81%
3Y Avg
-16.15%
5Y Avg
-23.71%
Market Cap
$209.91M
Return on Assets (ROA)
25.43%
TTM Avg
5.08%
3Y Avg
-10.27%
5Y Avg
-14.74%
Market Cap
$220.93M
Return on Assets (ROA)
-52.33%
TTM Avg
-30.08%
3Y Avg
-42.41%
5Y Avg
-37.62%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anbio Biotechnology Class A Ordinary Shares (NNNN) | $215.07M | 21.17% | 16.86% | 29.92% | N/A |
| Sionna Therapeutics, Inc. (SION)vs › | $214.46M | -34.38% | -28.15% | -48.34% | -48.34% |
| Niagen Bioscience Inc (NAGE)vs › | $214.24M | 15.00% | 14.43% | -2.68% | -18.26% |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.91M | -31.94% | -71.44% | -59.77% | -50.19% |
| Keros Therapeutics, Inc. (KROS)vs › | $218.30M | -28.91% | -2.34% | -20.04% | -20.00% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $210.98M | -79.86% | -75.29% | -50.35% | -41.02% |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.41M | -55.47% | -12.81% | -16.15% | -23.71% |
| Compugen Ltd. (CGEN)vs › | $209.91M | 25.43% | 5.08% | -10.27% | -14.74% |
| Profound Medical Corp. (PROF)vs › | $220.93M | -52.33% | -30.08% | -42.41% | -37.62% |
| Electra Therapeutics Inc. (ETRA)vs › | $208.31M | N/A | N/A | N/A | N/A |
ROA
21.2%
ROE
21.2%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 21.17% |
| 2024-12-31 | 12.54% |
| 2023-12-31 | 14.25% |
| 2022-12-31 | 71.72% |
| 2021-12-31 | 51.59% |
